Biotech RadarJobs updated

COMPANY

Equillium

HQ: La Jolla, CA source · equilliumbio.com ↗

Clinical Phase 3

Location: La Jolla, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Alopecia Areata Alopecia Totalis Alopecia Universalis Ulcerative Colitis Graft Versus Host Disease GVHD Acute-graft-versus-host Disease Acute GVHD aGVHD Alopecia EQ504 Itolizumab EQ101

$35.0MRaised (2 yrs)4Trials (company is sponsor)

Timeline

  1. Trial start I: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers source ↗
  2. Raise Private placement: $35M (total, as published), announced Mar 13, 2026. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 2: Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata source ↗
  4. Trial start Phase 3: A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) source ↗
  5. Trial start 2: Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $35.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT07869225A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy VolunteersINot yet recruiting2026-102027-04 (estimated)
NCT05263999A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)Phase 3TerminatedApr 29, 2022Apr 22, 2025 (actual)
NCT05589610Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataPhase 2CompletedDec 19, 2022Mar 26, 2024 (actual)
NCT03532958Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata2Withdrawn2021-102022-11 (estimated)
Feedback